In terms of patient prognosis, patients with high expression of MINDY1 have a higher 5-year tumor-free survival rate, while those with high expression of PD-L1 have a lower 5-year tumor-free survival rate, which is consistent with previous studies [19]. Here, MINDY1 is linked to neoplasm.